- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00570999
Palifermin After Haploidentical PBSCT (KGF Haplo Allo)
Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation
This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are randomised to receive either placebo or a keratinocyte growth factor (Palifermin or Kepivance®).
The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also been suggested to have an ability to help improve the reconstitution, or development, of the immune system after the transplantation.
The hypothesis is that the patients T-cell dependent humoral immune response to recall antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo control group
연구 개요
상태
개입 / 치료
연구 유형
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Würzburg, 독일, 97080
- Dr Ruth Seggewiss
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Recipient:
- Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or complete remission
- ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1 or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS)
- CML in chronic or accelerated phase
- Osteomyelofibrosis (OMF)
- Hodgkin lymphoma (HD) in partial or complete remission
- Age ≥18 years, ≤ 65 years
- ECOG status ≤2
- Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior local radiotherapy is allowed except radiation involving the thymus
- Adequate pulmonary function
- Left ventricular ejection fraction (LVEF) >30%
- Haploidentical related donor
- Failure to find matched related or matched unrelated donor and urgently requiring transplantation
- Planned conditioning regimen per Aversa or Würzburg protocol
- Women must be post-menopausal, sterile or use effective contraception and have a negative pregnancy test at study entry (β-HCG neg)
- Signed informed consent
Donor:
- Healthy family member
- Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3 HLA allele(s) on the unshared haplotype
- Donors must be capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central venous catheter should leukapheresis via peripheral vein be inadequate.
- Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell collection or should patient fail to demonstrate sustained engraftment
- Signed informed consent
Exclusion Criteria:
Recipient:
- History of or concurrent cancer (< 5 years ago) other than those named in inclusion criteria
- Primary chemorefractory disease
- CML in blast crisis
- MM with no or minor response to previous treatment
- Prior treatment with palifermin, or other keratinocyte growth factors
- Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component of the product
- Documented hypersensitivity to Prevenar vaccine or its components
- Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous transplantation
- Prior total body irradiation
- Post thymectomy
- Major anticipated illness or organ failure incompatible with survival from PBPC transplantation
- Active chronic skin disease requiring therapy
- Active inflammatory bowel disease requiring therapy
- Active uncontrolled infection
- Sero-positive HIV
- Pregnancy or breast-feeding
- Active invasive fungal tissue infection (EORTC criteria)
- 30 days or less since receiving an investigational product or device in another clinical trial
- Concurrent enrolment in another trial is not permitted unless the purpose is for long-term follow-up/survival data only, or observational only
- Chronic pancreatitis or history of acute pancreatitis within 1 year prior to transplant
- Psychiatric disorder associated with incompliance
- Myocardial infarction less than 3 months pre enrolment or EF <30% as measured in echocardiography/laevoventriculography
- Infusion of retrovirally or other transduced cells are not permitted.
- Planned intravenous application of immunoglobulins is contraindicated throughout the study period.
- Donor lymphocyte infusions are not allowed.
Donor:
- A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis infection.
- Evidence of any other active infection
- Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders, chronic inflammatory diseases) posing a health risk for peripheral blood stem cell harvest
- Hematopoietic or marrow function related disease interfering with the collection of sufficient numbers of normal progenitor cells
- Pregnancy or breast-feeding
- Any malignancy besides basal cell epithelioma or cured malignancy < 5 years ago
- Psychiatric disorder associated with incompliance
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm A
Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
|
60 mg/kg/day
다른 이름들:
|
위약 비교기: Arm B
Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
|
1,2 mL once daily
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)
기간: at study day +270 (20 days after the third Prevenar injection)
|
at study day +270 (20 days after the third Prevenar injection)
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation
기간: at study days: +240
|
at study days: +240
|
To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation
기간: Study days +210, +240, +270
|
Study days +210, +240, +270
|
To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections
기간: at 2 years
|
at 2 years
|
To assess drug related safety
기간: at 2 years
|
at 2 years
|
공동 작업자 및 조사자
협력자
수사관
- 연구 의자: Ruth Seggewiss, MD, University Hospital of Würzburg
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
만성 골수성 백혈병에 대한 임상 시험
-
Hospital Clinic of BarcelonaAstraZeneca완전한CTO(Chronic Total Occlusion)를 위한 PCI(Percutaneous Coronary Intervention)를 받을 예정인 환자스페인